| Name | Title | Contact Details |
|---|
LifeScript is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1996, Principals of Clearwater Living have been actively engaged in the ownership, operation, and development of high-quality senior living communities nationwide. More specifically, the Principals of Clearwater have been an integral part of creating various senior living platforms for operators as part of senior management. In 2011, Clearwater Living was formed for the sole purpose of providing entitled land and developing senior living communities for operators and their financial stakeholders. By combining best practices learned and aligning with top-of-class industry professionals, Clearwater Living`s primary objective is to expedite the process of supplying innovative projects to meet the growing demand of active adult and senior living communities. To further that goal, Clearwater Living and Berkshire Group entered into a joint venture in 2016. Through the joint venture, Clearwater Living will strategically acquire, develop and operate a full range of senior housing communities (including a mix of active adult, independent living, assisted living and memory care) throughout the Western United States. CWL is comprised of a high-performance real estate team utilizing our collective imagination, ingenuity and inventiveness in everything we do. Our passion is to create and manage high-quality senior living communities uniquely positioned and designed to complement their community and neighborhood culture.
Kahl and Associates is a Olympia, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RamSoft, Inc. is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.